DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Trial Evaluating Cardiovascular Outcomes With Sitagliptin



Trial Management

Executive Committee (EC)

The EC is responsible for the overall management, oversight and reporting of the trial.

Members    
Robert Califf US Cardiologist (Joint Chair)
Rury Holman UK Endocrinologist (Joint Chair)
     
Paul Armstong Canada Cardiologist
John Buse US Endocrinologist
Robert Josse Canada Endocrinologist
John Lachin US Statistician
Darren McGuire US Cardiologist
Eberhard Standl Germany Endocrinologist
Frans Van de Werf Belgium Cardiologist
     
Peter Stein US Merck
Joerg Koglin US Merck
Shailaja Suryawanshi US Merck
Scott Korn US Merck

Data Safety Monitoring Board (DSMB)

The DSMB will help ensure the safety of the trial participants by undertaking regular independent evaluation of trial safety data.

Members    
Marc Pfeffer US Cardiologist (Chair)
Hertzel Gerstein Canada Endocrinologist
Leif Groop Sweden Endocrinologist
John McMurray UK Cardiologist
Stuart Pocock UK Statistician

Operations Committee (OC)

The OC is comprised of country lead investigators selected by the Executive Committee, DTU and DCRI. The primary role of the OC is to serve as the interface between the EC and the trial sites and to monitor and supervise the progress of the trial at a regional level.

Study Sponsor

Merck